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Abstract: Hyperglycaemia is a prevalent complication in the neonatal 
intensive care unit (NICU) and is associated with worsened outcomes. It 
occurs as a result of prematurity, under developed endogenous glucose 
regulatory systems and clinical stress. The stochastic targeting (STAR) 
framework provides patient-specific, model-based glycaemic control with a 
clinically proven level of confidence on the outcome of treatment 
interventions, thus directly managing the risk of hypo- and hyper- 
glycaemia. However, stochastic models that are over conservative can limit 
control performance. Retrospective clinical data from 61 episodes (25 
retrospective and 36 from a prospective blood glucose control study) of 
insulin therapy in very-low birth weight (VLBW) and extremely-low birth 
weight (ELBW) neonates are used to create a new stochastic model of 
model-based insulin sensitivity (SI [L/mU/min]). Sub-cohort models based 
on gestational age (GA) and birth weight (BW) are also created. 
Performance is assessed by the percentage of patients who have 90% of 
actual intra-patient variability in SI captured by the 90% confidence bands 
of the cohort based (inter-patient) stochastic variability model created. This 
assessment measures per-patient accuracy for any given cohort model. 
 Per-patient coverage trends were very similar between prospective and 
retrospective cohorts, providing a measure of external validation of cohort 
similarity.  Per-patient coverage was improved though the use of BW and 
GA dependent stochastic models,  which ensures that the stochastic models 
more accurately capture both inter- and intra- patient variability. Stochastic 
models based on insulin sensitivities during insulin treatment periods are 
tighter and give better and safer glycaemic control. More patient specific 
methods, particularly in the modeling of endogenous insulin and glucose 
production, will be required to further improve forecasting and glycaemic 
control.  
Keywords: Insulin sensitivity, control algorithms, physiological models, 
simulation, intensive care 
 
  
 
 
     
 
1.0 INTRODUCTION 
Premature infants are a large proportion of neonatal intensive care unit (NICU) populations. 
Severity of prematurity is commonly quantified by gestational age (GA) and birth weight 
(BW). Birth weight classifies infants into low birth weight (LBW < 2,500g), very low birth 
weight (VLBW < 1,500g) and extremely low birth weight (ELBW < 1,000g). Similarly GA 
classifies prematurity as preterm (< 36 weeks), very preterm (< 31 weeks) and extremely 
preterm (< 27 weeks). Each classification carries increased risk of long term complications, 
impaired development, and mortality with decreasing BW and GA.  
Persistent hyperglycaemia is reported in 57% of ELBW infants (Hays et al., 2006), and in a 
study of VLBW infants 80% had blood glucose (BG) >8 mmol/L, 57% had BG>10 mmol/L, 
and 32% had BG>10 mmol/L for more than 10% of the time (Beardsall et al., 2010). 
Hyperglycaemia is typically regarded as BG greater than 10mmol/L, but there is no standard 
definition, nor an accepted threshold for intervention (Alsweiler et al., 2007). 
Hyperglycaemia has been linked to worsened outcome, but no study has conclusively 
determined if hyperglycaemia itself is harmful, or simply represents severity of condition. 
The associated negative outcomes include sepsis, increased ventilator dependence, 
retinopathy of prematurity, increased hospital length of stay, and mortality (Alaedeen et al., 
2006; Heimann et al., 2007). 
The approach to managing hyperglycaemia is different for each NICU, but effective 
treatment remains elusive. Current treatments include glucose restriction, and insulin. 
However, glucose restriction  (Hemachandra et al., 1999) deprives the neonate of energy vital 
for growth and development (Cowett et al., 2004), and is therefore not ideal.  The use of 
insulin infusions to treat hyperglycaemia and/or promote growth has shown positive 
outcomes including reduced proteolysis, improved glucose tolerance, increased insulin-like 
 
 
     
 
growth factor (IGF-I) levels, and improved caloric intake and weight gain (Agus et al., 2004; 
Beardsall, Ogilvy-Stuart, et al., 2007; Beardsall et al., 2008). 
 
 However, many insulin trials were unsuccessful in safely providing glycaemic control due to 
increased hypoglycaemia (Beardsall et al., 2008; Meetze et al., 1998). All reported insulin 
therapy trials used protocols that fixed insulin dosing based on weight or other factors  
(Beardsall, Vanhaesebrouck, et al., 2007)  or depended on clinical judgement to determine 
insulin infusion rates. Implicitly, these protocols assume a fixed insulin sensitivity, and so 
these protocols fail to account for the large intra- and inter-patient variability observed in the 
insulin sensitivity of neonates (Le Compte et al., 2010; Le Compte et al., 2012).  Increased 
variability with fixed or relatively fixed insulin dosing protocols results in poor control, 
excessive glycaemic variability and hypoglycaemia (Chase et al., 2011).  
 
STAR (Stochastic TARgeting) is a model based glycaemic control framework  (Le Compte et 
al., 2009; Le Compte et al., 2012) for insulin therapy that uses a time varying insulin 
sensitivity (SI [L/mU/min]) to provide an adaptive patient-specfic response that allows for 
both inter-patient variability and future intra-patient variability over time. This insulin 
sensitivity characterises a patient’s current metabolic state, and likely future changes in that 
state are forecast using population based stochastic modelling. A range of possible future 
insulin sensitivity outcomes is generated based on a patient’s current insulin sensitivity, and 
this enables a treatment to be selected that best overlaps the range of possible BG outcomes 
with a clinically defined target band. The algorithm for STAR is shown in the appendix. 
STAR has been the clinical standard of care in Christchurch Women’s Hospital since 2009. 
 
 
 
     
 
The performance of STAR is dependent on the effectiveness of stochastic modelling; poor 
stochastic forecasting results in poor glycaemic control. High variability in insulin sensitivity 
over time and between patients has been shown to limit possible performance of glycaemic 
control in simulation (Dickson et al.).  High variability results in overly conservative 
stochastic models for some neonates, with wide stochastic forecasting bands that are not 
representative of all neonates resulting in low doses of insulin and persistently high BG. To 
enable better and equally safe control for all patients, the stochastic models need to be 
improved. One avenue is to create stochastic models for the variation of SI over specific sub-
cohorts by GA and BW, which are variables readily available at bedside. The goal is to create 
models that not only account for inter-patient variability over cohorts, but also capture intra-
patient variability (per-patient) more accurately. This is done through a retrospective analysis 
of insulin sensitivities from clinical data. Quantification of variability and its sources will 
enable tighter glycaemic control without sacrificing safety.  
  
 
 
     
 
2.0 METHODS 
2.1  System model 
The clinically validated  NICING model (Le Compte et al., 2009) describes glucose-insulin 
dynamics in the extremely preterm neonate. The model is described by the ordinary 
differential equations (ODEs) shown in Equations 1-7. Model parameters and variables are 
defined in Table 1, and the model is shown pictorially in Figure 1.  
The rate of change of plasma glucose (?̇?) is defined in Equation. 1: 
?̇? = −𝑝𝐺𝐺(𝑡) −  𝑆𝐼𝐺(𝑡) 𝑄(𝑡)1 +  𝛼𝐺𝑄(𝑡)   + 𝑃(𝑡) +  𝐸𝐺𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦 − 𝐶𝑁𝑆 ∗ 𝑚𝑏𝑟𝑎𝑖𝑛𝑉𝑔,𝑓𝑟𝑎𝑐(𝑡) ∗ 𝑚𝑏𝑜𝑑𝑦  (1) 
Insulin-mediated glucose clearance is determined by insulin sensitivity (𝑆𝐼) and non insulin-
mediated uptake includes a general clearance term, including kidney clearance, (𝑝𝐺) and a 
central nervous system uptake (CNS). Glucose sources include exogenous glucose (𝑃(𝑡)) and 
endogenous production (𝐸𝐺𝑃). 
The rate of change of plasma (𝐼)̇ and interstitial (?̇?)  insulin are defined in Equations 2-4: 
𝐼̇ =  −  𝑛𝐿𝐼(𝑡)1 +  𝛼𝐼𝐼(𝑡) − 𝑛𝐾𝐼(𝑡) − 𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)� +  𝑢𝑒𝑥(𝑡)𝑉𝐼,𝑓𝑟𝑎𝑐 ∗ 𝑚𝑏𝑜𝑑𝑦 + (1 − 𝑥𝐿)𝑢𝑒𝑛 (2) 
𝑢𝑒𝑛 =  IB𝑒−𝑘𝐼𝑢𝑒𝑥𝑉𝐼  (3) 
?̇? =  𝑛𝐼�𝐼(𝑡) − 𝑄(𝑡)� −  𝑛𝐶 𝑄(𝑡)1 +  𝛼𝐺𝑄(𝑡) (4) 
Plasma insulin is cleared via the liver (𝑛𝐿), the kidney (𝑛𝐾) and transport into interstitial fluid 
(𝑛𝐼). Insulin enters the system exogenously (𝑢𝑒𝑥 ) or endogenously (𝑢𝑒𝑛)  through pancreatic 
secretion, as described in Eqn. 3. Insulin leaves the interstitial fluid through degradation (𝑛𝐶). 
Appearance of glucose via the enteral route is modelled via two intermediary compartments, 
the stomach (𝑃1) and the gut (𝑃2), and is described in Equations 5-7. 
?̇?1 =  −𝑑1𝑃1 + 𝑃(𝑡) (5) 
?̇?2 =  −min(𝑑2𝑃2,𝑃𝑚𝑎𝑥) + 𝑑1𝑃1 (6) 
 
 
     
 
𝑃(𝑡) = min(𝑑2𝑃2,𝑃𝑚𝑎𝑥) + 𝑃𝑁(𝑡) (7) 
Transport rates between the stomach and gut, and gut and blood (𝑑1 and 𝑑2 respectively) are 
limited to a maximum flux (𝑃𝑚𝑎𝑥). Solutions to equations 1-7 (giving profiles for G,I,Q,P1 
and P2) are generated simultaneously in the time domain using a Runga-Kutta 4 based ODE 
solver.  
 
 
Figure 1: Pictorial representation of the NICING model. 
 
 𝑆𝐼  is patient specific and time varying, describing a patients current metabolic state. It is fit 
using integral based fitting methods (Hann et al., 2006) on a retrospective hour-to-hour basis, 
and assumed constant over an hour-long period. In addition to being a marker of peripheral 
insulin sensitivity, 𝑆𝐼  also incorporates uncertainty around patient-specific endogenous 
insulin and glucose production. A 𝑆𝐼 of zero represents the lower physiological bound in 
insulin sensitivity where no glucose is leaving the blood plasma via the insulin-mediated 
uptake path. 
 
 
     
 
Table 1: Glucose-insulin metabolic model variable definition 
Variable Description Values 
G Blood glucose level (mmol/L) 
I Plasma insulin concentration (mU/L) 
Q Interstitial insulin concentration (mU/L) 
pG Endogenous glucose clearance 0.0030 (min−1) 
αG Saturation parameter for insulin mediated glucose removal 0 (L/mU) 
αI Saturation parameter for plasma  insulin clearance 0.0017 (L/mU) 
SI Insulin sensitivity (L/mU/min) 
EGP Endogenous glucose production 0.0284 
(mmol/kg/min) 
CNS Central nervous system glucose uptake 0.088 (mmol/kg/min) 
P(t) Glucose appearance in plasma from dextrose intake (mmol/min) 
PN Parenteral Nutrition (mmol/min) 
Pmax Maximal glucose flux from gut to plasma 6.11 (mmol/min) 
P1 Glucose level in stomach (mmol) 
P2 Glucose level in gut (mmol) 
VG Plasma glucose distribution volume 0.5961 (L) 
kI Interstitial insulin transport rate 0.1 (min−1) 
IB Endogenous insulin production 15 (mU/L/min) 
nI Rate of transport between plasma and interstitial insulin 
compartments 
0.003 (min-1)  
nK Renal insulin clearance 0.150(min−1) 
nL Hepatic insulin clearance 1 (min−1) 
nC Interstitial insulin degradation 0.003 (min−1) 
𝑥𝐿 First-pass hepatic insulin clearance 0.67 
uex(t) Exogenous insulin (mU/min) 
uen(t) Endogenous insulin production (mU/L/min) 
VI Plasma insulin distribution volume 0.0450 (L) 
d1 Glucose absorption rate from stomach 0.0347 (min−1) 
d2 Glucose absorption rate from gut 0.0069 (min−1) 
D(t) Dextrose intake (mmol/min) 
𝑚𝑏𝑜𝑑𝑦 Body mass (kg) 
𝑚𝑏𝑟𝑎𝑖𝑛 Brain mass (14% 𝒎𝒃𝒐𝒅𝒚) (kg) 
  
 
 
     
 
2.2  Clinical Patients and Insulin Sensitivity Fitting 
SI profiles were fit using integral based fitting (Hann et al., 2006) from clinical data using 
Equations 1-7. This clinically validated metric and method (Chase et al., 2010) allows the 
performance and stochastic forecasting of STAR to be optimised before clinical trials. The 
integral based fitting method can be used since SI is constant across an hour long time 
interval. If this time interval is bounded by 𝑡1 and 𝑡2, SI can be solved for by the re-arranging 
of the integrated form of Equation 1 for SI, giving Equation 8.  
𝑆𝐼 = −�𝐺(𝑡2) − 𝐺(𝑡1)� + ∫ �−𝑝𝐺𝐺(𝑡) + 𝑃(𝑡) +  𝐸𝐺𝑃 ∗ 𝑚𝑏𝑜𝑑𝑦 − 𝐶𝑁𝑆 ∗ 𝑚𝑏𝑟𝑎𝑖𝑛𝑉𝑔,𝑓𝑟𝑎𝑐(𝑡) ∗ 𝑚𝑏𝑜𝑑𝑦 �𝑡2𝑡1 𝑑𝑡
∫ �
𝑄(𝑡)1 +  𝛼𝐺𝑄(𝑡)�𝑡2𝑡1 𝑑𝑡    (8) 
 The start and end BG for each hour of clinical data,  𝐺(𝑡2) and𝐺(𝑡1), is approximated using 
linear interpolation between BG measures. The SI  profile of a patient consists of a constant SI 
identified for each hour of clinical data. 
The patient cohort, summarised in Table 2, consists of data from 21 retrospective patients 
(with 25 patient episodes), and 8 short term and 22 long term patients from a prospective BG 
control study using STAR. The 8 short term patients received insulin therapy for 24 hours in 
a validation trial of the existing model and controller (Le Compte et al., 2009).  Long term 
patients were treated using STAR as a standard of care at Christchurch Women’s Hospital. 
There are 61 clinical patient datasets, as there are 28 treatment episodes for the 22 long term 
patients. 
Table 2: Clinical patient summary statistics. 
 Short-term (N=8) Long-term (N=28) Retrospective (N=25) 
Median [IQR] Median [IQR] Median [IQR] 
Gestational age at birth 
 (weeks) 25.6 [24.9 - 26.4] [25.4 [25.0 - 26.8] 26.6 [25.4 - 27.7] 
Weight at birth 
 (grams) 745 [681 - 814] 760 [601 - 925] 845 [800 - 904] 
Age at start of trial  
(days) 6.6 [3.6 - 7.7] 3.6 [1.5 - 6.4] n/a 
 
 
 
     
 
2.3  Improving Stochastic Forecasting with Increased Cohort 
The current stochastic model used in the STAR controller was designed using a retrospective 
cohort of 25 patients (Le Compte et al., 2010). Hence, the relevance of its performance in 
virtual trials may be limited. A stochastic matrix created using the larger 61 virtual patient 
cohort is compared to the current stochastic matrix.  
 
The stochastic model used for SI forecasting is generated from changes in insulin sensitivity 
across a retrospective representative clinical patient population. Changes in SI can be seen 
when a SI value (𝑆𝐼,𝑛) is plotted against the 𝑆𝐼value 1-4 hours forward (𝑆𝐼,𝑛+1), as shown in 
Figure 2. No change would result in a straight line with gradient 1. Kernel density methods 
are used to generate a distribution of likely future values of  𝑆𝐼 for each sensitivity for which 
an example is shown in Figure 2.  Forecasting is achieved using the 5th and 95th percentiles of 
likely 𝑆𝐼 outcome.  
 
Performance of retrospective and prospective clinical sub-cohort based stochastic models is 
compared with a whole cohort model over 3-hour forecast intervals. A perfect stochastic 
model would capture 90% of each individual patient’s variations in the 5-95th percentile 
interval, but this may vary for individual patients. Performance of each stochastic model is 
assessed by the percentage of patients whose individual stochastic performance comes close 
to this ideal, for a more accurate and general the stochastic model.  
 
 
     
 
 
Figure 2: Hourly insulin sensitivity variation data with probability bounds and example 
curve showing probability bounds (Le Compte et al., 2010).  
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2.4  Improving Stochastic Forecasting in Sub-Cohorts 
Two variables easily identified at the bedside are birth weight (BW) and gestational age 
(GA). Stochastic model matrices are created for each sub-cohort generated by tertiles in BW 
or GA. A Kolmogorov–Smirnov (KS) test was used to identify the most significantly 
different patient sub-cohort groupings by absolute SI and hour-to-hour changes in SI. Sub-
cohort groupings were arranged by BW or GA. BW based sub-cohorts were arranged in 
several ways: 1) by tertiles and 2) into two groups with the critical BW ranging from 700 to 
1300g in 5 gram steps. Similarly GA sub-cohorts were arranged by: 1) tertiles, and 2) two 
groups with the critical GA ranging from 24 to 25 weeks. From the patient sub-cohort 
groupings that were most different (p<0.005) additional stochastic models were created to 
differentiate behaviours in SI. Performance is assessed using per-patient coverage.  
 
 
2.5 Improving Stochastic Forecasting using only Insulin Sensitivities from Insulin therapy 
periods 
Inherent in the clinical data are periods of several hours in length where the patient has not 
received at exogenous insulin. These periods tend to occur at the conclusion of a patient 
episode and reflect the improving ability of a patient to regulate their own plasma glucose 
levels. Stochastic models were developed using only the patient data in which exogenous 
insulin had been given sometime within the last two hours. Performance is assessed using 
per-patient coverage, and is directly compared to the non-insulin specific case. 
2.6 Clinically validated virtual trial methods 
 
 
     
 
The effect of stochastic modelling on the tightness and performance of glycaemic control can 
be evaluated through clinically validated virtual trial methods (Chase et al., 2010). Virtual 
trials test the effect of insulin and nutrition treatments on a virtual patient’s blood glucose by 
using a known, treatment independent (Chase et al., 2010), insulin sensitivity profile derived 
from clinical data. Future information is ignored and the simulation algorithm in Appendix 2 
is followed. The change in blood glucose levels over the intervention interval is then 
simulated using the known insulin sensitivity profile. Control performance outcomes are 
measured in the percentage time in the 4-8mmol/L band, percentage BG>10 mmol/L, and 
safety is evaluated in the percentage BG<4.0 mmol/L and number of incidences of BG<2.6 
mmol/L. 
  
 
 
     
 
3.0 RESULTS 
3.1  Stochastic Forecasting with Increased Cohort 
Figure 3 shows the per-patient coverage of the 5th to 95th percentile of forecasted change in SI 
for the current (N=25) and new (N=61) whole-cohort stochastic models. There is no 
significant difference between the per-patient coverage of the different stochastic matrices.  
Both stochastic matrices have a minimum coverage over 70% and tight distributions around 
90%. This result provides a measure of external validation in that the retrospective (N=25) 
cohort showed similar behaviour and performance to the prospective (N=36) cohort. The 
same results can be seen for 2 and 4 hour measurement intervals (not shown). However, 
small improvements can be seen in the coverage distribution for the new whole-cohort 
stochastic matrix (N=61). It is important to note that Figure 3 is the per-patient coverage, and 
not all patients have equal numbers of measurements and thus, do not have the same 
weighting on stochastic model forecast limits. In addition, manipulation of stochastic 
matrices to bring the overall whole-cohort percentage coverage closer to the target 90% tends 
to adjust the percentiles to capture a single data point, thus making the matrix more cohort-
specific and adding no extra value for use outside of the existing cohort. 
3.2  Gestational Age and Birth Weight Sub-Cohort 
The cumulative distribution functions (CDFs) of SI for tertiles of is shown in Figures 3. The 
CDFs of SI when separated by GA (<25.1 weeks, >26.9weeks, and between 25.1 and 26.9 
weeks) are almost identical to Figure 4. The lower tertile has significantly lower SI than the 
other groups for both GA and BW (p < 0.05, KS-test). In both cases, the relative changes in 
SI (lower plot) are not significantly different. Thus, these tertiles are different in absolute SI, 
but not in hour-to-hour variability. 
  
 
 
     
 
 
 
Figure 3: Per-patient coverage between the forecasted 5th and 95th, and 25th and 75th, percentile change in 
insulin sensitivity using the current stochastic matrix compared with new stochastic matrix.  (N = number of 
patients used to create stochastic matrix). 
 
Table 3 shows the results for the tertiles in Figures 4, as well as other statistically significant 
cut-off values found (p < 0.05) for SI over BW and GA sub-cohorts. Figure 5 shows the 
resulting per-patient coverage for stochastic forecasting using stochastic model for each of 
the weight tertiles, on comparison to a whole cohort stochastic model. There is noticeable 
improvement from the whole cohort (N=61) result shown for comparison, with increased 
patient coverage around 90%. This result was typical for all the stochastic model 
combinations shown in Table 3. Thus, the BW and GA dependent models add greater 
resolution and per-patient accuracy. 
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Table 3: Effect of weight and gestational age on insulin sensitivity statistics. 
Data Set SI  -Median [IQR] 
(L/mU/min) 
Relative delta SI – 
Median (P) [IQR] 
# hours #Patients 
Whole Cohort 0.0017 [0.0010 - 0.0027] 0.004204 [-0.0303 - 0.0351] 6968 61 
BW<700g 0.0013 [0.0007 - 0.0020] 0.004116 [-0.0299 - 0.0339] 3032 20 
BW>865g 0.0020 [0.0013 - 0.0031] 0.006074 [-0.0289 - 0.0376] 1426 20 
700g<BW<865g 0.0021 [0.0013 - 0.0032] 0.003114 [-0.0312 - 0.0360] 2510 21 
BW<805g 0.0015 [0.0008 - 0.0025] 0.003640 [-0.0310 - 0.0344] 4566 32 
BW>925g 0.0024 [0.0015 - 0.0037] 0.008583 [-0.0194 - 0.0353] 748 12 
805g<BW<925g 0.0019 [0.0013 - 0.0030] 0.003678 [-0.0312 - 0.0385] 1654 17 
BW<700g 0.0013 [0.0007 - 0.0020] 0.004116 [-0.0299 - 0.0339] 3032 20 
BW>700g 0.0021 [0.0013 - 0.0032] 0.004254 [-0.0305 - 0.0369] 3907 40 
BW<800g 0.0014 [0.0007 - 0.0021] 0.003866 [-0.0289 - 0.0334] 3519 27 
BW>800g 0.0021 [0.0013 - 0.0033] 0.004446 [-0.0315 - 0.0382] 3449 34 
GA<25.1wks 0.0013 [0.0007 - 0.0021] 0.004001 [-0.0314 - 0.0343] 3196 22 
GA>26.9wks 0.0020 [0.0013 - 0.0032] 0.008319 [-0.0215 - 0.0370] 1200 16 
25.1<GA<26.9 wks 0.0020 [0.0013 - 0.0031] 0.002614 [-0.0316 - 0.0364] 2572 23 
GA<26.15wks 0.0015 [0.0008 - 0.0026] 0.003139 [-0.0316 - 0.0340] 4561 34 
GA>27.05wks 0.0021 [0.0014 - 0.0033] 0.008422 [-0.0205 - 0.0374] 1141 14 
26.15wks< GA <27.05 wks 0.0019 [0.0013 - 0.0027] 0.004314 [-0.0315 - 0.0389] 1266 13 
GA<26.3 wks 0.0015 [0.0008 - 0.0026] 0.003138 [-0.0310 - 0.0340] 4842 37 
GA>26.3 wks 0.0020 [0.0014 - 0.0030] 0.007230 [-0.0287 - 0.0385] 2126 24 
GA<27.05 wks 0.0016 [0.0009 - 0.0026] 0.003364 [-0.0316 - 0.0349] 5827 47 
GA>27.05 wks 0.0021 [0.0014 - 0.0033] 0.008422 [-0.0205 - 0.0374] 1141 14 
 
 
  
Figure 4: Correlation of insulin sensitivity and 
change in insulin sensitivity with birth weight 
Figure 5: Comparison of per-patient coverage for BW 
and GA dependent point to point 3 hourly stochastic 
forecasting. 
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3.4 Low patient coverage case studies 
Given that the whole cohort stochastic models have ~ 90% overall coverage in the 5-95th 
percentile band, patients with individual coverage less than 85% were extracted for further 
analysis. As can be seen in Table 4 there is no common characteristic that could potentially 
be used to identify such patients as more variable. The patients summarised in Table 4 cover 
the entire range for both gestational age and birth weight. Furthermore, analysis of the per-
patient coverage statistics of the entire patient cohort shows no trends with birth weight, 
gestational age or gender, and while, in general,  a patient with low coverage of the 5th to 95th 
percentile band also had low coverage of the 25th-75th band (defined as coverage less than 
45%), the same was not true in reverse. 
Table 4: Highly variable patient statistics. LT denotes patients from the long term cohort, R denotes 
patients from the retrospective cohort 
Patient 
Number: 
# 
Hours 
% in  
5th – 95th 
band 
% above 
95th  
percentile 
% in  
25th – 75th 
band 
% above 
75th 
percentile 
Birth 
weight 
Gestational 
age 
LT 21 272 75.1 10.0 30.9 33.5 0.605 25 
LT 27 28 80.0 12.0 28.0 48.0 0.69 24.6 
R 6 93 73.3 17.8 33.3 38.8 0.900 25 
R 10 66 76.2 19.0 38.9 42.8 1.28 27.9 
R 12 34 80.6 19.4 29.0 35.5 0.845 28.6 
R 19 44 82.9 17.1 43.9 36.5 0.93 28.6 
 
  
 
 
     
 
 
 
a) 
 
b) 
Figure 6: Clincial data and SI profiles for two highly variable patients: a) Retrospective patient 19 and b) 
Long Term patient 21 
 
Figure 6 shows two high variability profiles derived from clinical data. In Figure 6 a) the SI 
rises unusually fast and unusually high, whereas in Figure 7 b) the SI exhibits sudden peaks 
and drops. In particular, it is the sudden increases in SI beyond the forecasted bounds that can 
result in unexpectedly low BG. For this reason, when carrying out virtual trials, the highly 
variable patients tend to constitute unrepresentative, larger proportions of the low BG 
(BG<4.0 mmol/L) time periods, which means the stochastic matrices remain overly 
conservative for the remainder of the cohort. The SI of the other high variability patients from 
Table 4 generally exhibit aspects of both these example profiles, and are difficult to visually 
identify as differing from the rest of the cohort without looking at per-patient coverage. 
Patients that are variable with respect to the cohort are thus hard to identify in the clinical 
situation with the limited bedside metrics available. 
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3.5 Stochastic matrices based on periods of insulin therapy 
The analysis was carried out using SI from time periods in clinical data when a patient had 
been on insulin within the last two hours. This removed the increase in SI common at the end 
of a patient’s clinical data, when they are not receiving insulin treatments and their BG is 
basal and stable. This increase in SI reflects an improvement in patient condition. Figure 6 
shows the difference made to per patient coverage. The narrowing of stochastic forecasting 
bands is evident in Figure 7 with the lower overall patient coverage, and the clear distribution 
around 90% coverage. There was no difference in the results for trends with BW and GA. 
 
Figure 7: Per-patient coverage between the forecasted 5th and 95th percentile change in insulin sensitivity using 
the current stochastic matrix compared with an insulin periods only stochastic model. The clinical data used to 
generate the insulin periods stochastic model ignores any data where insulin has not been given within the last 2 
hours. 
 
3.6 Simulation Results  
Clinically validated virtual trials using the stochastic matrix from insulin periods showed a 
10% increase in performance (% BG between 4.0 and 8.0 mmol/L), and a drop in the number 
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of hypoglycaemic events (BG <2.6 mmol/L) from 4 to 2 patients. This result shows that using 
insulin-period-based stochastic modelling increases the performance and safety of glycaemic 
control.  
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4.0 DISCUSSION 
 
Comparison of per-patient percentile band coverage for different cohort based stochastic 
matrices has shown that the cohorts are essentially similar in behaviour. The addition of 36 
patient episodes (N=25 to N=61) has improved per-patient stochastic model coverage 
slightly, but not to an extent that is likely to be clinically significant in use. This similarity in 
coverage with the use of different cohort stochastic forecasting verifies that the original data 
set is as representative of the NICU population as previously thought,  where initial work 
with stochastic matrices in adult ICU patients indicated N = 25 would be suitable (Lin et al., 
2006).  
The high proportion of coverage above 90%, and in particular above 95% in the 5-95th band 
suggests that this band width is determined by the behaviour of a relative few patients. 
Ideally, for patient specificity, the majority of per-patient coverage would be close to the 
target 90%. The patient coverage of the 25-75th percentiles is much wider, indicating 
significant inter-patient variability and lack of patient-specific coverage within these central 
tendency bounds. In particular, the short and long term cohorts tend to have higher average 
coverage in the 25th-75th band suggesting that differences between cohorts arise within the 
extremes of behaviour, and that estimates of variability are over conservative in the majority 
of cases. Overall it seems that inter-patient variation is more significant than intra-patient 
variation as a limiting factor in this stochastic forecasting model, and that a relative few more 
variable patients are quite different in behaviour.  
BW and GA dependent stochastic models can be used to further improve per-patient 
coverage, as seen in Figure . The proportion of coverage around the 90% target for the 5-95th 
percentiles is much greater, indicating BW and GA can be used to introduce greater patient 
specificity in stochastic forecasting. Due to the relatively small number of patients used, the 
ideal combinations of BW and GA found may not fully represent all NICU populations or be 
 
 
     
 
perfect divisions for other NICU cohorts. Equally, there may be differences between NICUs 
due to differences in cohort or case mix. However, the results clearly illustrate potential to 
improve patient-specific forecasting and glycaemic control based on easily measured 
variables. Further investigations using larger independent cohorts should be completed to 
validate these initial insights, and create more generalisable results. However, these results 
provide a template for further analysis. 
A small proportion of patients from this cohort exhibit changes in SI that is not well predicted 
by the whole cohort and birth weight divisional stochastic models. These patients do not have 
any readily identifiable patient descriptor, such as birth weight or gestational age, in common. 
However, these patients can be roughly divided according to their exogenous insulin 
requirements. Several patients had high insulin sensitivity and did not require exogenous 
insulin to maintain constant BG. Their SI was not well predicted by the model due to 
improvement of patient condition, exacerbating per-patient variability and deviance from 
modelled insulin and glucose secretion, and thus they are in no danger as high insulin 
sensitivity will result in no treatment. These cases highlight model specificity for describing 
glucose and insulin dynamics in the neonate with deficient glycaemic control. 
The other type of patient with SI profiles that were not well predicted by the model were 
those with high variability due to rapid fluctuations in patient condition, most likely due to 
changes in insulin and glucose secretion. This case is more serious as exogenous insulin is 
required, and a rapid increase in insulin sensitivity can lead to a decrease in BG levels. Such 
patients highlight the need for well designed insulin dosing protocols with safety checks. 
Currently, in addition to forward prediction of likely BG outcomes, STAR applies a 
maximum limit on the amount by which insulin can increase from treatment to treatment. 
This limit is dependent on BG and protects highly variable patients from excessive insulin 
therapy.  
 
 
     
 
There was a decrease in average percentage time in band and shift in distribution to around 
90% when using SI only from periods where a patient had received insulin. The new 
stochastic bands are tighter and therefore less conservative, but better reflect patient condition 
and variability for patients actually receiving insulin, as shown in the improved coverage of 
the target band (4.0-8.0 mmol/L) and lower number of patients with hypoglycaemic events.  
It also suggests that the 7 patients with percentage time in band less than 60% have higher 
insulin sensitivity, and thus, as seen in the data, received less insulin therapy. In addition, 
uncertainty around the endogenous glucose and insulin secretion is highlighted, particularly 
in the patient recovery stage. This result gives direction for future work in better 
quantification of variability around endogenous secretion of insulin and glucose. It also 
underlines the models specificity for use in patients requiring insulin therapy. 
 
  
 
 
     
 
5.0 CONCLUSIONS 
Stochastic model based forecasting based on a larger patient database provides a more 
accurate representation of the NICU population, but is limited by inter-patient variability.  
Birth weight and gestational age dependent stochastic forecasting can be used to further 
increase per-patient accuracy and coverage. The use of stochastic models based on insulin 
sensitivities from insulin treatment periods better reflected patient condition in control, as 
reflected by the 10% increase in percentage time in band and the halving of the number of 
patients with hypoglycaemic events.  Further improvement can be achieved through 
investigations into the variability associated with endogenous insulin and glucose production. 
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APPENDIX 1: STAR algorithm 
 
 
*Currently nutrition is clinically modulated. In the adult ICU STAR modulates both nutrition 
and insulin to optimise glycaemic control. 
  
 
 
     
 
APPENDIX 2: Virtual trial simulation algorithm 
  
*Currently nutrition is clinically modulated. In the adult ICU STAR modulates both nutrition 
and insulin to optimise glycaemic control. 
